馃攷 Adjuvant atezolizumab is linked to beneficial estimated 2-year DFS and OS rates, respectively, in patients with stage III MSI-H or dMMR #colorectalcancer who were ineligible for oxaliplatin-based chemotherapy, according to results presented at #ESMO26: https://buff.ly/nny8s6x
13 views 路 0 likes 路 0 reposts 路 0 replies
Phase II randomized trial of carboplatin, pemetrexed, and bevacizumab with and without atezolizumab in stage IV non-squamous non-small cell lung cancer (NSCLC) patients who harbor a sensitizing EGFR mutation or have never smoked
https://esmocongress.esmo.orgZL 1310 (DLL3 ADC) plus atezolizumab 卤 carboplatin in extensive-stage small cell lung cancer: Part 1b/1c results from study ZL 1310 001
https://esmocongress.esmo.orgFinal overall survival (OS) results from BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase 3 trial of first-line atezolizumab (atezo), chemotherapy (CT) and bevacizumab (bev) for metastatic, persistent or recurrent cervic
https://esmocongress.esmo.orgSource: GI Oncology Now 路 x.com